STOCK TITAN

Apnimed Q3 2026 net loss widens to $29.5M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Apnimed, Inc. (APMD) reported third-quarter 2026 results while its NDA for AD109, with proposed name Oxnimbi, remains under FDA review; the FDA assigned a February 28, 2027 PDUFA goal date. AD109 has completed two Phase 3 trials for mild, moderate and severe obstructive sleep apnea (OSA). Apnimed presented five abstracts at CHEST 2026, including two late-breakers, and is advancing commercial readiness for a potential U.S. launch, subject to FDA approval.

Cash and cash equivalents were $351.8 million at September 30, 2026, which Apnimed said is expected to fund a potential U.S. launch and operations into the second quarter of 2028. Third-quarter related-party revenue was $2.480 million, compared with $8.802 million a year earlier; research and development expense was $11.812 million versus $9.754 million, and general and administrative expense was $22.628 million versus $6.045 million. Net loss was $29.524 million, compared with $10.910 million. The company attributed part of higher G&A to $4.0 million of launch-preparation infrastructure and $4.4 million of stock-based compensation. Its August 2026 upsized IPO raised approximately $198.9 million in net proceeds.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.$351.8 million cash is expected to fund operations into Q2 2028.

Negative

  • Moderate pointRelated-party revenue was $2.480 million versus $8.802 million in Q3 2025.
  • Moderate pointNet loss was $29.524 million, versus $10.910 million in Q3 2025.

Filing Explained

Nine-month reported net income included gains from an investment sale and reversal of a deposit liability; the third-quarter result was a loss.

The furnished third-quarter statements report 41,630,779 common shares outstanding at September 30, 2026, versus 4,781,256 at December 31, 2025. That higher share count means a fixed holding represents a smaller percentage ownership, absent offsetting changes, while the statements also report no preferred shares outstanding and a $0 liquidation preference at September 30, versus 25,934,116 preferred shares and a $224,518 thousand liquidation preference at year-end 2025.

For the nine months ended September 30, 2026, reported net income was $164,130 thousand, including an $85,380 thousand gain on sale of an equity-method investment and a $57,120 thousand gain on reversal of a deposit liability.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash and cash equivalents $351.8 million As of September 30, 2026; expected to fund a potential U.S. launch and operations into the second quarter of 2028
Related-party revenue $2.480 million Three months ended September 30, 2026; $8.802 million in the same 2025 period
Research and development expenses $11.812 million Three months ended September 30, 2026; $9.754 million in the same 2025 period
General and administrative expenses $22.628 million Three months ended September 30, 2026; $6.045 million in the same 2025 period
Net loss $29.524 million Three months ended September 30, 2026; $10.910 million in the same 2025 period
IPO net proceeds Approximately $198.9 million Upsized initial public offering completed in August 2026
PDUFA goal date February 28, 2027 FDA review of the NDA for AD109
New Drug Application (NDA) regulatory
"New Drug Application (“NDA”) for AD109"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
PDUFA goal date regulatory
"assigned a PDUFA goal date of February 28, 2027"
The PDUFA goal date is the target deadline set by the U.S. Food and Drug Administration for completing its review of a new drug or biologic application. Investors watch it like a court date for a product: the outcome (approval, rejection, or request for more information) can sharply change a company’s revenue prospects and stock price, and the date gives a predictable event around which markets and planning can focus.
obstructive sleep apnea (OSA) medical
"treatment of adults with obstructive sleep apnea (“OSA”)"
A sleep disorder where a person repeatedly stops breathing or breathes very shallowly during sleep because the airway partly or fully closes, causing snoring, daytime tiredness, and other health risks. Investors care because it drives demand for medical devices, diagnostics, treatments, and ongoing healthcare costs—similar to a chronic equipment failure in a factory that reduces output and increases maintenance and regulatory oversight, affecting revenue, reimbursement and long‑term market growth.
antimuscarinic medical
"aroxybutynin, a novel antimuscarinic"
A class of drugs that block muscarinic acetylcholine receptors, which are proteins on nerve and muscle cells that respond to the neurotransmitter acetylcholine. By reducing these signals, antimuscarinics relax smooth muscle and reduce secretions, so they are used for conditions like overactive bladder, some respiratory disorders, and gastrointestinal spasms. For investors, the term matters because antimuscarinic compounds have specific efficacy and side‑effect profiles, regulatory pathways, and market demand that affect a drug candidate's commercial and approval prospects.
selective norepinephrine reuptake inhibitor medical
"atomoxetine, a selective norepinephrine reuptake inhibitor"
hypoxic burden medical
"baseline hypoxic burden as a potential marker of blood pressure response"
Hypoxic burden is a measure of how much and how long a person's blood oxygen levels fall below normal, combining the depth and duration of low-oxygen events into a single score. Investors care because it is used to evaluate the severity of respiratory and sleep disorders, guide treatment decisions, and influence demand for medical devices, drugs and diagnostics — like knowing how often and how badly a car runs low on fuel, which affects maintenance and replacement needs.
Related-party revenue $2.480 million Down from $8.802 million in Q3 2025.
Research and development expenses $11.812 million Up 20% from $9.754 million in Q3 2025.
General and administrative expenses $22.628 million Up from $6.045 million in Q3 2025; the company reported an increase greater than 100%.
Net loss $29.524 million loss Compared with $10.910 million loss in Q3 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Apnimed's APMD Q3 2026 revenue and net loss?

Apnimed reported $2.480 million in related-party revenue and a $29.524 million net loss for the three months ended September 30, 2026; the comparable 2025 figures were $8.802 million and a $10.910 million net loss.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001745648False00017456482026-11-132026-11-13

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

APNIMED, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-43422

82-1910611

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

Apnimed, Inc.

39 John F. Kennedy Street, 4th Floor

Cambridge, MA 02138

(Address of principal executive offices, including zip code)

(617) 500-8880

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share

APMD

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

Item 2.02

Results of Operations and Financial Condition

 

On November 16, 2026, Apnimed, Inc. issued a press release announcing its financial results for the quarterly period ended September 30, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits

99.1 Press release of the Company, dated November 16, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Apnimed, Inc.

Date: November 16, 2026

By:

/s/ Kevin R. Lind

Kevin R. Lind

Chief Executive Officer

 


 

EX-99.1

Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update

•
New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review with a February 28, 2027, Prescription Drug User Fee Act (“PDUFA”) goal date
•
Commercial readiness activities advance in preparation for a potential U.S. launch
•
Presented five abstracts at CHEST 2026, including two late-breakers, highlighting AD109 Phase 3 clinical data and the burden of OSA
•
$351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028

CAMBRIDGE, Mass., November 16, 2026– Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We are in a transformational period at Apnimed,” said Kevin Lind, Chief Executive Officer of Apnimed. “With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story. At CHEST, we presented new analyses in postmenopausal women, on baseline hypoxic burden as a potential marker of blood pressure response, and on patient-reported outcomes. We believe this growing body of evidence is important to establishing the potential role of Oxnimbi for the millions of adults with OSA who remain untreated.”

Recent Highlights and Upcoming Milestones

•
The NDA for AD109 (proposed proprietary name Oxnimbi) for the treatment of adults with obstructive sleep apnea (“OSA”) remains under review by the FDA. The FDA has assigned a PDUFA goal date of February 28, 2027.
•
Continued to advance commercial readiness activities, including market access and payer engagement, commercial team and go-to-market build-out, and manufacturing and distribution preparation, to support a potential U.S. launch of Oxnimbi, subject to FDA approval.
•
Presented five abstracts at the American College of Chest Physicians’ CHEST 2026 Annual Meeting: three featuring Phase 3 AD109 data, including two late-breakers and one on patient-reported outcomes, and two real-world studies on the burden of OSA. The meeting also featured a CHEST-led panel discussion on the results of the Phase 3 SynAIRgy and LunAIRo trials and their potential application to OSA management.
•
Completed its upsized initial public offering in August 2026, raising approximately $198.9 million in net proceeds. With $351.8 million in cash and cash equivalents as of September 30, 2026, the Company is well positioned to support commercial readiness and the potential U.S. launch of Oxnimbi, if approved by the FDA.

Third Quarter Financial Results

Cash Position

Apnimed reported cash and cash equivalents of approximately $351.8 million at September 30, 2026.


 

Research and Development Expenses

Research and development expenses were $11.8 million for the three months ended September 30, 2026, an increase of $2.0 million, or 20%, compared to $9.8 million for the three months ended September 30, 2025. The net increase was primarily due to:

•
An increase of $2.1 million in medical affairs expense, driven by increased Key Opinion Leader (“KOL”) engagement in 2026;
•
Higher employee-related expenses of $1.3 million; and
•
Higher stock-based compensation of $0.6 million.

These increases were partially offset by $2.0 million of lower clinical trial expense related to AD109 (proposed proprietary name Oxnimbi), as we focus on commercial launch.

General and Administrative Expenses

General and administrative expenses were $22.6 million for the three months ended September 30, 2026, an increase of $16.6 million, or greater than 100%, compared to $6.0 million for the three months ended September 30, 2025. The net increase was primarily related to:

•
$8.1 million in professional services incurred related to business consulting and contract negotiations, IT infrastructure, and increased salary and related employee expenses due to increased headcount;
•
$4.0 million in infrastructure to prepare the Company, the market, and the Company’s brand for the potential launch of AD109 (proposed proprietary name Oxnimbi), if approved, including key areas such as education on the unmet needs in OSA, pricing strategy, forecast estimates, market access planning, product positioning and stakeholder messaging; and
•
$4.4 million in stock-based compensation related to increased headcount and modifications of certain equity awards.

Other Income

Other income was $2.7 million for the three months ended September 30, 2026, an increase of $2.4 million, or greater than 100%, compared to $0.3 million for the three months ended September 30, 2025. The net increase was primarily related to:

•
A $1.6 million increase in interest income; and
•
A $1.2 million increase in fair value of long-term debt.

These increases were partially offset by a $0.3 million change in fair value of revenue interest liability.

Net Loss

Net loss was $29.5 million for the quarter ended September 30, 2026, compared to a net loss of $10.9 million for the quarter ended September 30, 2025. The increase was primarily attributable to the factors impacting the Company’s expenses and other income described above.

About AD109 / Oxnimbi

AD109 is Apnimed’s investigational drug candidate, with a proposed proprietary name Oxnimbi. The proposed name remains subject to final FDA review and acceptance and may change. AD109 is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in adults with OSA. It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. AD109 is intended to be a once-daily oral pill taken at bedtime that is designed to lower the complexity of treating OSA. AD109 may offer an oral solution to help improve oxygenation and health for adults living with OSA. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed’s NDA for AD109 is under review by the FDA and was assigned a PDUFA goal


 

date of February 28, 2027. There can be no assurances that AD109 will be approved by the FDA by the PDUFA goal date, or at all.

About Apnimed

Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Apnimed believes the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for adults with OSA. Apnimed believes that adults with OSA would benefit from having multiple treatment options with differing mechanisms to more fully address the heterogeneity of OSA’s disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention and expand the reach of diagnosis and treatment.

Apnimed is advancing its product candidate, AD109 (proposed proprietary name Oxnimbi), which is designed to improve oxygenation in adults living with OSA. Apnimed believes that Oxnimbi could become the catalyst for a new oral treatment paradigm for OSA, which has historically been limited to devices or invasive surgeries.

Learn more at apnimed.com or follow us on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “envisions,” “will,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, without limitation, statements regarding our expectations as to commercial readiness activities and launch, the potential approval and commercialization of Oxnimbi, the potential acceptance of Oxnimbi as the proprietary name for AD109, the clinical and therapeutic potential of Oxnimbi (including to address or catalyze a new treatment paradigm for OSA), the size of the commercial opportunity for Oxnimbi, the occurrence and timing of the PDUFA goal date for Oxnimbi, and other statements that are not historical facts. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.

Forward-looking statements are based on our current expectations, estimates and projections only as of the date of this release and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in biopharmaceutical product development; our ability to execute on our strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; risks related to our financial condition and the need for substantial additional funding in order to complete development activities and commercialize Oxnimbi; risks related to the competitive landscape for OSA products; our ability to attract, integrate and retain key personnel; risks related to regulatory developments and approval processes of the FDA and comparable foreign regulatory authorities; and risks related to establishing and maintaining our intellectual property protections. These and other risks and uncertainties concerning our business and operations are described more fully in the section titled “Risk Factors” of our most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking statements contained in this announcement are made as of this date, and Apnimed undertakes no duty to update such information except as required under applicable law.

Media Contact:

media@apnimed.com

Investor Contact:

ir@apnimed.com


 

APNIMED, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in thousands, except share and per share amounts)

 

 

 

September 30, 2026

 

 

December 31, 2025

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

 

$

351,826

 

 

$

41,890

 

Prepaid research and development costs

 

 

1,881

 

 

 

1,541

 

Accounts receivable

 

 

588

 

 

 

959

 

Prepaid expenses and other current assets

 

 

6,661

 

 

 

665

 

Total current assets

 

 

360,956

 

 

 

45,055

 

PROPERTY AND EQUIPMENT, NET

 

 

46

 

 

 

66

 

ASSETS HELD FOR SALE

 

 

—

 

 

 

26,893

 

CONTINGENT ASSET

 

 

9,812

 

 

 

—

 

OPERATING LEASE RIGHT-OF-USE ASSET

 

 

652

 

 

 

835

 

OTHER ASSETS

 

 

24

 

 

 

24

 

TOTAL ASSETS

 

$

371,490

 

 

$

72,873

 

LIABILITIES, CONVERTIBLE PREFERRED STOCK AND
   STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Accounts payable

 

$

4,326

 

 

$

1,788

 

Accrued expenses and other current liabilities

 

 

15,068

 

 

 

11,026

 

Operating lease liability

 

 

273

 

 

 

250

 

Short-term deferred revenue

 

 

17,296

 

 

 

97,812

 

Total current liabilities

 

 

36,963

 

 

 

110,876

 

LONG TERM LIABILITIES:

 

 

 

 

 

 

Operating lease liability, net of current

 

 

414

 

 

 

623

 

Convertible notes

 

 

—

 

 

 

40,646

 

Debt

 

 

39,059

 

 

 

—

 

Revenue interest liability

 

 

10,297

 

 

 

—

 

Deposit liability

 

 

—

 

 

 

57,120

 

Deferred revenue

 

 

—

 

 

 

15,244

 

TOTAL LIABILITIES

 

 

86,733

 

 

 

224,509

 

COMMITMENTS AND CONTINGENCIES (NOTE 7)

 

 

 

 

 

 

Convertible Preferred Stock, $0.00001 par value, no shares and 25,934,116 shares
   authorized as of September 30, 2026 and December 31, 2025, respectively; no shares and
   25,934,116 shares issued and outstanding as of September 30, 2026 and December 31, 2025,
   respectively. Liquidation preference of $0 and $224,518 as of September 30, 2026 and
   December 31, 2025, respectively.

 

 

—

 

 

 

221,147

 

STOCKHOLDERS’ EQUITY (DEFICIT):

 

 

 

 

 

 

Preferred stock, $0.00001 par value, 10,000,000 and no shares authorized as of September 30,
   2026 and December 31, 2025, respectively; no shares issued or outstanding as of either date.

 

 

—

 

 

 

—

 

Common stock, $0.00001 par value, 500,000,000 shares authorized as of September 30, 2026
   and 45,627,228 (42,481,983 Class A, 2,948,668 Class B, and 196,577 Class C) shares
   authorized as of December 31, 2025; 41,630,779 shares issued and outstanding as of
   September 30, 2026 and 4,781,256 (1,832,588 Class A, 2,752,091 Class B, and 196,577
   Class C) shares issued and outstanding as of December 31, 2025.

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

517,970

 

 

 

24,560

 

Accumulated deficit

 

 

(233,214

)

 

 

(397,344

)

Total stockholders’ equity (deficit)

 

 

284,757

 

 

 

(372,783

)

TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND
   STOCKHOLDERS’ EQUITY (DEFICIT)

 

$

371,490

 

 

$

72,873

 

 

 

 

 

 


 

APNIMED, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

REVENUE - RELATED PARTY

 

$

2,480

 

 

$

8,802

 

 

$

99,374

 

 

$

29,043

 

OPERATING EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

11,812

 

 

 

9,754

 

 

 

29,816

 

 

 

49,179

 

General and administrative

 

 

22,628

 

 

 

6,045

 

 

 

41,808

 

 

 

16,868

 

Cost of services - related party

 

 

245

 

 

 

1,987

 

 

 

3,615

 

 

 

5,028

 

Total operating expenses

 

 

34,685

 

 

 

17,786

 

 

 

75,239

 

 

 

71,075

 

INCOME (LOSS) FROM OPERATIONS

 

 

(32,205

)

 

 

(8,984

)

 

 

24,135

 

 

 

(42,032

)

OTHER INCOME (EXPENSES):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

1,814

 

 

 

263

 

 

 

3,002

 

 

 

1,003

 

Gain on reversal of deposit liability

 

 

—

 

 

 

—

 

 

 

57,120

 

 

 

—

 

Change in fair value of long-term debt

 

 

1,208

 

 

 

—

 

 

 

(451

)

 

 

—

 

Change in fair value of revenue interest liability

 

 

(260

)

 

 

—

 

 

 

(720

)

 

 

—

 

Change in fair value of convertible notes

 

 

—

 

 

 

—

 

 

 

1,315

 

 

 

—

 

Other expense

 

 

(81

)

 

 

—

 

 

 

(2,819

)

 

 

—

 

Total other income

 

 

2,681

 

 

 

263

 

 

 

57,447

 

 

 

1,003

 

NET INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES

 

 

(29,524

)

 

 

(8,721

)

 

 

81,582

 

 

 

(41,029

)

Income tax expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

NET INCOME (LOSS) FROM CONTINUING OPERATIONS

 

 

(29,524

)

 

 

(8,721

)

 

 

81,582

 

 

 

(41,029

)

Gain on sale of equity method investment

 

 

—

 

 

 

—

 

 

 

85,380

 

 

 

—

 

Loss from discontinued operations

 

 

—

 

 

 

(2,189

)

 

 

(2,832

)

 

 

(68,001

)

NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS

 

 

—

 

 

 

(2,189

)

 

 

82,548

 

 

 

(68,001

)

NET INCOME (LOSS)

 

$

(29,524

)

 

$

(10,910

)

 

$

164,130

 

 

$

(109,030

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - Basic:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(1.05

)

 

$

(1.83

)

 

$

6.46

 

 

$

(8.62

)

Discontinued operations

 

$

—

 

 

$

(0.46

)

 

$

6.54

 

 

$

(14.29

)

Basic net income (loss) per share

 

$

(1.05

)

 

$

(2.29

)

 

$

13.00

 

 

$

(22.91

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - Diluted:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(1.05

)

 

$

(1.83

)

 

$

4.75

 

 

$

(8.62

)

Discontinued operations

 

$

—

 

 

$

(0.46

)

 

$

4.88

 

 

$

(14.29

)

Diluted net income (loss) per share

 

$

(1.05

)

 

$

(2.29

)

 

$

9.63

 

 

$

(22.91

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic

 

 

28,019,494

 

 

 

4,768,110

 

 

 

12,621,882

 

 

 

4,756,996

 

Weighted average common shares outstanding, diluted

 

 

28,019,494

 

 

 

4,768,110

 

 

 

16,903,129

 

 

 

4,756,996

 

 


Filing Exhibits & Attachments

2 documents

Keep reading